Arecor Therapeutics plc (AREC.L) Research

Arecor Therapeutics PLC is a biopharmaceutical enterprise dedicated to creating therapies for diabetes and various other medical conditions. The company utilizes its exclusive Arestat formulation technology platform to both cultivate its own range of specialized products (for diabetes and other ailments) and collaborate with pharmaceutical and biotechnology partners to refine and enhance existing therapeutic formulations. Its pipeline includes AT247, an exceptionally fast-acting insulin aimed at individuals with Type I and Type II diabetes, and AT278, a highly concentrated rapid-acting insulin formulation engineered to hasten insulin absorption following injection. Established in 2007, the company's main office is situated in Little Chesterford, United Kingdom.

Market snapshot

Symbol
AREC.L
Price
$62.50
Day change
0.00%
Market cap
$23.6M
P/E ratio
35.51x
52-week range
42-100
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 3 months

Peer companies

  • Aptamer Group plc (APTA.L)
  • Fusion Antibodies plc (FAB.L)
  • Genflow Biosciences plc (GENF.L)
  • Hemogenyx Pharmaceuticals Plc (HEMO.L)
  • IXICO plc (IXI.L)
  • Novacyt S.A. (NCYT.L)
  • OptiBiotix Health Plc (OPTI.L)
  • Poolbeg Pharma PLC (POLB.L)

Open Arecor Therapeutics plc (AREC.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.